TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 126.8% in August

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totalling 68,500 shares, an increase of 126.8% from the August 15th total of 30,200 shares. Based on an average daily volume of 167,400 shares, the short-interest ratio is presently 0.4 days.

TC Biopharm Price Performance

NASDAQ:TCBP opened at $6.56 on Friday. TC Biopharm has a 12 month low of $2.11 and a 12 month high of $138.00. The business’s 50-day moving average is $6.16 and its two-hundred day moving average is $10.43. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.88 and a quick ratio of 0.88.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.